Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis

American Journal of Pathology

Volumn 169, Issue 5, 2006, Pages 1567-1576

  Cuenca, Jimena ^a   Martín Sanz, Paloma ^a,b   Álvarez Barrientos, Alberto M ^a   Boscá, Lisardo ^a,b   Goren, Nora ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYCLOOXYGENASE 2; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PROSTANOID; MMP9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; INFLAMMATION; INFLAMMATORY CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SEPTICEMIA; ANIMAL; C57BL MOUSE; CELL SEPARATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; RAT;

ANIMALS; CELL SEPARATION; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; MYOCARDIUM; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE II; RATS; SEPSIS;

EID: 34548153451     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060109     Document Type: Article

References (45)

1. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993, 328:1471-1477
3. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012
4. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A: Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 1998, 98:100-103
5. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994, 91:2046-2050
6. Liu W, Nakamura H, Shioji K, Tanito M, Oka S, Ahsan MK, Son A, Ishii Y, Kishimoto C, Yodoi J: Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004, 110:1276-1283
7. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P: Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004, 95:700-707
8. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR: Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001, 103:155-160
9. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci USA 2000, 97:12746-12751
10. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262
11. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001, 89:201-210
12. Maier JA, Hla T, Maciag T: Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 1990, 265:10805-10808
13. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP: Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol 2004, 286:H1416-H1424
14. Saito T, Rodger IW, Hu F, Shennib H, Giaid A: Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000, 273:772-775
15. Scheuren N, Jacobs M, Ertl G, Schorb W: Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 2002, 34:29-37
16. Marcet-Palacios M, Graham K, Cass C, Befus AD, Mayers I, Radomski MW: Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther 2003, 307:429-436
17. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, De Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M, Cuccurullo F, Mezzetti A: Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482-1488
18. Poon BY, Raharjo E, Patel KD, Tavener S, Kubes P: Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation 2003, 108:1107-1112
19. Ungureanu-Longrois D, Balligand JL, Kelly RA, Smith TW: Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol 1995, 27:155-167
20. Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF: Role of nitric oxide in antagonistic effects of transforming growth factor-β and interleukin-1β on the beating rate of cultured cardiac myocytes. Mol Endocrinol 1992, 6:1921-1930
21. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992, 105:575-580
22. Goren N, Cuenca J, Martin-Sanz P, Bosca L: Attenuation of NF-κB signalling in rat cardiomyocytes at birth restricts the induction of inflammatory genes. Cardiovasc Res 2004, 64:289-297
23. Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, Rosenzweig A, Chao W: MyD88 and NOS2 are essential for Toll-like receptor 4 (TLR4)-mediated survival effect in cardiomyocytes. Am J Physiol 2006, 291:H1900-H1909
24. Chagnon F, Metz CN, Bucala R, Lesur O: Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ Res 2005, 96:1095-1102
25. Lam ML, Bartoli M, Claycomb WC: The 21-day postnatal rat ventricular cardiac muscle cell in culture as an experimental model to study adult cardiomyocyte gene expression. Mol Cell Biochem 2002, 229:51-62
26. Gomez AM, Benitah JP, Henzel D, Vinet A, Lorente P, Delgado C: Modulation of electrical heterogeneity by compensated hypertrophy in rat left ventricle. Am J Physiol 1997, 272:H1078-H1086
27. Fernandez-Martinez A, Callejas NA, Casado M, Bosca L, Martin-Sanz P: Thioacetamide-induced liver regeneration involves the expression of cyclooxygenase 2 and nitric oxide synthase 2 in hepatocytes. J Hepatol 2004, 40:963-970
28. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254
29. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH: Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997, 323:603-609
30. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H: Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004, 22:1007-1015
31. Shen Y, Xu W, Chu YW, Wang Y, Liu QS, Xiong SD: Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol 2004, 78:12548-12556
32. Luster AD: The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002, 14:129-135
33. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL: Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998, 153:417-428
34. Koh KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC, Tellides G, Pober JS: T cell-mediated vascular dysfunction of human allografts results from IFN-γ dysregulation of NO synthase. J Clin Invest 2004, 114:846-856
35. Kim MP, Zhou M, Wahl LM: Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005, 78:195-201
36. Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA: Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 2005, 446:369-378
37. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Berry MF, Burdick J, Bhalla RC, Sharma RV, Gardner TJ, Sweeney HL: Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 2004, 110:II180-II186
38. Luckow B, Joergensen J, Chilla S, Li JP, Henger A, Kiss E, Wieczorek G, Roth L, Hartmann N, Hoffmann R, Kretzler M, Nelson PJ, Perez de Lema G, Maier H, Wurst W, Balling R, Pfeffer K, Grone HJ, Schlondorff D, Zerwes HG: Reduced intragraft mRNA expression of matrix metalloproteinases MMP3, MMP12, MMP13 and ADAM8, and diminished transplant arteriosclerosis in CCR5-deficient mice. Eur J Immunol 2004, 34:2568-2578
39. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL: Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005, 111:1800-1805
40. Khan KM, Howe LR, Falcone DJ: Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem 2004, 279:22039-22046
41. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002, 105:1816-1823
42. Wang W, Viappiani S, Sawicka J, Schulz R: Inhibition of endogenous nitric oxide in the heart enhances matrix metalloproteinase-2 release. Br J Pharmacol 2005, 145:43-49
43. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL: Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol 2005, 288:H461-H468
44. Egi K, Conrad NE, Kwan J, Schulze C, Schulz R, Wildhirt SM: Inhibition of inducible nitric oxide synthase and superoxide production reduces matrix metalloproteinase-9 activity and restores coronary vasomotor function in rat cardiac allografts. Eur J Cardiothorac Surg 2004, 26:262-269
45. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005, 6:150-166